#USA #New York #Elacestrant #Menarini Group #ASCO 2026

Menarini Group's Latest Advances Highlighted at ASCO 2026

On May 25, 2026, Menarini Group, a prominent international pharmaceutical and diagnostic entity, showcased crucial innovations at the American Society of Clinical Oncology (ASCO) annual meeting. With a dedication to addressing challenging cancers, Menarini presented new data spanning seven significant presentations focusing on solid tumors and hematological malignancies. This event underscored their commitment to advancing cancer therapies that cater to unmet medical needs.

Among the key highlights was the presentation of the ELEVATE study, examining the combination of elacestrant and capivasertib in metastatic breast cancer patients. The data revealed promising potential benefits for patients, prompting discussions about elacestrant’s role not only as a combination therapy but also as a monotherapy option in adjuvant settings. Furthermore, updates from various ongoing clinical trials involving elacestrant were disclosed, illustrating its pivotal role in breast cancer treatment progression.

Elcin Barker Ergun, CEO of Menarini Group, emphasized, "The wealth of oncology data presented reflects our resolve to tackle the most difficult cancers that lack effective treatment options. We are relentlessly focused on accelerating innovations to provide transformative targeted therapies that offer meaningful advancements for patients and healthcare communities."

The ELEVATE study highlighted how elacestrant may provide a new pathway for patients whose cancers have mutated along specific pathways, such as ER+/HER2- PI3K/AKT/PTEN. In addition, other trials were presented, including:

• - ADELA: A phase 3 pivotal trial assessing elacestrant combined with everolimus against elacestrant plus placebo in ER+/HER2- patients with mutated ESR1 tumors.
• - ELECTRA: A phase 1b/2 study exploring elacestrant's safety and efficacy in tandem with abemaciclib for patients with brain metastases derived from ER+/HER2- breast cancer.
• - CAPELA: This phase 2 multi-center study maps the outcomes of elacestrant combined with capecitabine versus capecitabine alone in ER-positive, advanced breast cancer.

Menarini's cutting-edge approaches did not stop there. The company also disclosed phase 2 results for tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), further emphasizing their versatility in targeting various cancers. Naveen Pemmaraju, MD, from the MD Anderson Cancer Center, delivered findings from the clinical trial which showcased tagraxofusp's efficacy and safety.

Moreover, an unexpected last-minute presentation came from Stemline Therapeutics, a subsidiary of Menarini Group. They presented findings from the phase 3 SENTRY trial, assessing selinexor in myelofibrosis patients who haven't undergone treatment with JAK inhibitors. This work represents a significant step forward in the quest for novel treatments in various types of hematological cancers.

The ASCO 2026 meeting not only highlighted Menarini’s ongoing commitment to cancer therapy innovations but also set the stage for future discussions on potential collaborations and studies that aim to extend the therapeutic reach of emerging treatments.

As the event concluded, the overarching message was clear: Menarini Group remains dedicated to transforming the landscape of oncology through rigorous research and an unwavering focus on patient-centered care. Their recent presentations at ASCO 2026 reinforce their pivotal role in evolving cancer treatment protocols, thereby impacting countless lives positively. The anticipation for the results from upcoming studies signals a promising horizon in cancer research and treatment advancements.

For additional details on Menarini's presentations and ongoing clinical trials, please visit their official website.